Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice

article has not abstract

Vyšlo v časopise: Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice. PLoS Med 10(2): e32767. doi:10.1371/journal.pmed.1001389
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001389

Souhrn

article has not abstract

Zdroje

1. McGettiganP, HenryD (2013) Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 10: e1001388 doi:10.1371/journal.pmed.1001388.

2. BombardierC, LaineL, ReicinA, ShapiroD, Burgos-VargasR, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528.

3. BresalierRS, SandlerRS, QuanH, BologneseJA, OxeniusB, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102.

4. SinghS, WuO, LanghorneP, MadhokR (2006) Risk of acute myocardial infarction with non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8: R153 doi:10.1186/ar2047.

5. McGettiganP, HenryD (2006) Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclo-oxygenase. JAMA 296: 1633–1644 doi:10.1001/jama.296.13.jrv60011.

6. KearneyP, BaigentC, GoodwinJ, HallsH, EmbersonJ, PatronoC (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308.

7. FosbølEL, FolkeF, JacobsenS, RasmussenJN, SørensenR, et al. (2010) Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3: 395–405.

8. García RodríguezLA, TacconelliS, PatrignaniP (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628–1636.

9. TrelleS, ReichenbachS, WandelS, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: A network meta-analysis. BMJ 342: c7086 doi:10.1136/bmj.c7086.

10. GrosserT, FriesS, FitzGeraldGA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4–15.

11. Government of India, Ministry of Health & Family Welfare (2011) National list of essential medicines of India. Available: http://cdsco.nic.in/National%20List%20of%20Essential%20Medicine-%20final%20copy.pdf. Accessed 28 November 2012.

12. LaingR, WaningB, GrayA, FordN, ‘tHoenE (2003) 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361: 1723–1729.

13. ReddyKS (2004) Cardiovascular disease in non-Western countries. N Engl J Med 350: 2438–2440.

14. WHO (2011) Global status report on noncommunicable diseases 2010. Geneva: World Health Organization. Available: http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed 28 November 2012.